Trial · NCT04295642
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Single Dose: Peak Plasma Concentration | Day 1 to 12 | Peak Plasma Concentration (Cmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose:Area under the plasma concentration-time curve | Day 1 to 12 | Area under the plasma concentration-time curve (AUC) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose: Area under the plasma concentration-time curve from time zero to infinity | Day 1 to 12 | Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose: Time to Maximum Concentration | Day 1 to 12 | Time to Maximum Concentration (Tmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Peak Plasma Concentration | Day 16 to 29 | Peak Plasma Concentration (Cmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Area under the plasma concentration-time curve | Day 16 to 29 | Area under the plasma concentration-time curve (AUCτ) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Time to Maximum Concentration | Day 16 to 29 | Time to Maximum Concentration (Tmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Secondary | Secondary Outcome (AE) Number of subjects with reported Treatment Emergent Adverse Events (TEAEs) | up to Day 35 | Number of subjects with reported Treatment Emergent Adverse Events (TEAEs) |
| Secondary | Secondary Outcome (Labs) Number of subjects with clinically significant changes in laboratory measures | up to Day 35 | Number of subjects with clinically significant changes in laboratory measures |
| Secondary | Secondary Outcome (ECGs)Number of subjects with Clinically significant changes in Electrocardiogram | up to Day 35 | Number of subjects with Clinically significant changes in Electrocardiogram measures (PR,RR,QT and QTcF) |
| Secondary | Secondary Outcome (Vital Signs) Number of subjects with Clinically meaningful changes in Vital signs | up to Day 35 | Number of subjects with Clinically meaningful changes in Vital signs |
| Secondary | Secondary Outcome (C-SSRS) - Change from baseline of the Columbia-Suicide Severity Rating Scale(C-SSRS) | up to Day 35 | Change from baseline of the Columbia-Suicide Severity Rating Scale(C-SSRS) The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04295642/registered